|Intercept Rises After Data Shows Liver Disease Drug Works|
... its design for a Phase 3 trial, which is the last step typically needed before approval. The company plans to target the drug first on a rare disease called primary biliary cirrhosis, in which inflammation destroys bile ducts in the liver and leads ...
Bloomberg - Tue, 12 Aug 2014 08:15
|Drug to Treat Fatty Liver Disease Found Effective|
Newsmax Health - Tue, 12 Aug 2014 09:18
|Intercept Pharma (Nasdaq: ICPT) Stock Skyrockets 45% on Liver Disease ...|
Money Morning - Tue, 12 Aug 2014 08:58
|Intercept Pharma Soars On Liver-Disease Drug Data ICPT|
Investor's Business Daily - Tue, 12 Aug 2014 07:48
|Intercept (ICPT) Stock Rockets on Earnings, Positive Drug Results|
InvestorGuide - Tue, 12 Aug 2014 06:41
|New Guideline Addresses Management of Focal Liver Lesions|
... noncancerous lesions such as hepatocellular adenomas and biliary cystadenomas have malignant potential. These lesions may not necessarily present with symptoms attributable to the lesion and are frequently not associated with underlying liver disease.
Medscape - Mon, 25 Aug 2014 13:03
|Intercept to Present at Upcoming Investor Conferences|
The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases including primary biliary cirrhosis (PBC), ...
MarketWatch - Tue, 26 Aug 2014 05:06
|Zumba for Liam|
This disease causes the bile ducts to develop abnormally and blocks the flow of bile from the liver to the intestines leading to liver damage, cirrhosis and eventual death. At 9 months, Baby Liam underwent surgery - the Kasai procedure-connecting his ...
Sun.Star - Wed, 27 Aug 2014 11:33
|Study outlines risk factors for solid organ cancers after liver transplantation|
Risk was reduced for recipients who received tacrolimus, compared with cyclosporine A (0.56), and for patients who had primary biliary cirrhosis/primary sclerosing cholangitis (0.47) or hepatitis C infection (0.21) as the indication for transplantation ...
The Oncology Report - Tue, 26 Aug 2014 12:41
|What You Need to Know About Jaundice|
... of the skin. However, understanding why jaundice occurs gives people living with liver disease the information they need to better monitor their health. ... One of the liver's functions is to produce and secrete bile into the intestines to help ...
LiverSupport.com - Mon, 11 Aug 2014 08:30
|East Coast Biotech Roundup: Amicus, Accelerator, Seventh Sense, & More|
The company should file an FDA application for OCA in primary biliary cirrhosis next year as well. —Cambridge-based Vertex Pharmaceuticals (NASDAQ: VRTX) revealed in a letter written to healthcare providers this week that it will stop selling ...
Xconomy - Fri, 15 Aug 2014 06:53
|Why Intercept Is Up 324% This Year|
Intercept's drug Obeticholic acid (OCA), which will be used to treat primary biliary cirrhosis (PBC), is in Phase III trials. If approved by the US Food and Drug Administration (FDA), the blockbuster drug is expected to be ... eventually lead to death ...
Bidness Etc - Mon, 18 Aug 2014 05:03